JPH03279860A - Inspecting method and inspecting reagent - Google Patents
Inspecting method and inspecting reagentInfo
- Publication number
- JPH03279860A JPH03279860A JP8195190A JP8195190A JPH03279860A JP H03279860 A JPH03279860 A JP H03279860A JP 8195190 A JP8195190 A JP 8195190A JP 8195190 A JP8195190 A JP 8195190A JP H03279860 A JPH03279860 A JP H03279860A
- Authority
- JP
- Japan
- Prior art keywords
- antibodies
- label
- substance
- detected
- materials
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 42
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 11
- 239000000427 antigen Substances 0.000 claims abstract description 16
- 102000036639 antigens Human genes 0.000 claims abstract description 16
- 108091007433 antigens Proteins 0.000 claims abstract description 16
- 230000005855 radiation Effects 0.000 claims abstract description 10
- 238000010521 absorption reaction Methods 0.000 claims abstract description 6
- 238000007689 inspection Methods 0.000 claims abstract description 6
- 238000012360 testing method Methods 0.000 claims description 33
- 239000000126 substance Substances 0.000 claims description 25
- 230000002285 radioactive effect Effects 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 abstract description 9
- 108090000623 proteins and genes Proteins 0.000 abstract description 9
- 238000005259 measurement Methods 0.000 abstract description 6
- 238000006243 chemical reaction Methods 0.000 abstract description 5
- 239000000203 mixture Substances 0.000 abstract description 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 4
- 239000007788 liquid Substances 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract 6
- -1 for example Proteins 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 8
- 239000000758 substrate Substances 0.000 description 7
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 108010014173 Factor X Proteins 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 108030001720 Bontoxilysin Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 229940053031 botulinum toxin Drugs 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 102000013415 peroxidase activity proteins Human genes 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- OBYNJKLOYWCXEP-UHFFFAOYSA-N 2-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]-4-isothiocyanatobenzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(N=C=S)=CC=C1C([O-])=O OBYNJKLOYWCXEP-UHFFFAOYSA-N 0.000 description 2
- KUWPCJHYPSUOFW-YBXAARCKSA-N 2-nitrophenyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1[N+]([O-])=O KUWPCJHYPSUOFW-YBXAARCKSA-N 0.000 description 2
- XQXPVVBIMDBYFF-UHFFFAOYSA-N 4-hydroxyphenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C=C1 XQXPVVBIMDBYFF-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 238000004847 absorption spectroscopy Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 229960005156 digoxin Drugs 0.000 description 2
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 2
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000001506 fluorescence spectroscopy Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 2
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 2
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
- YFGBQHOOROIVKG-BHDDXSALSA-N (2R)-2-[[(2R)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound C([C@H](C(=O)N[C@H](CCSC)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 YFGBQHOOROIVKG-BHDDXSALSA-N 0.000 description 1
- BCHIXGBGRHLSBE-UHFFFAOYSA-N (4-methyl-2-oxochromen-7-yl) dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C=CC2=C1OC(=O)C=C2C BCHIXGBGRHLSBE-UHFFFAOYSA-N 0.000 description 1
- JWICNZAGYSIBAR-LEEGLKINSA-N (4s)-4-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-5-[[2-[[(2s)-3-carboxy-1-[[(2s)-1-[[1-[[(2s)-1-[[(2s)-4-carboxy-1-[[2-[[2-[[2-[[(2s)-1-[[(1s)-1-carboxy-4-(diaminomethylideneamino Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)C(CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)N)CC1=CC=CC=C1 JWICNZAGYSIBAR-LEEGLKINSA-N 0.000 description 1
- GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- SPSSULHKWOKEEL-UHFFFAOYSA-N 2,4,6-trinitrotoluene Chemical compound CC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O SPSSULHKWOKEEL-UHFFFAOYSA-N 0.000 description 1
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- YUDPTGPSBJVHCN-DZQJYWQESA-N 4-methylumbelliferyl beta-D-galactoside Chemical compound C1=CC=2C(C)=CC(=O)OC=2C=C1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YUDPTGPSBJVHCN-DZQJYWQESA-N 0.000 description 1
- IETDBZQIWIJQJG-UHFFFAOYSA-N 7-hydroxy-2-oxo-chromene-3-carboxylic acid ethyl ester Chemical compound C1=C(O)C=C2OC(=O)C(C(=O)OCC)=CC2=C1 IETDBZQIWIJQJG-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102400001364 Alpha-1-microglobulin Human genes 0.000 description 1
- 101800001761 Alpha-1-microglobulin Proteins 0.000 description 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 1
- 101710083889 Alpha-fetoprotein Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000006734 Beta-Globulins Human genes 0.000 description 1
- 108010087504 Beta-Globulins Proteins 0.000 description 1
- 102400000748 Beta-endorphin Human genes 0.000 description 1
- 101800005049 Beta-endorphin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000113 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 108010075016 Ceruloplasmin Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 102100021809 Chorionic somatomammotropin hormone 1 Human genes 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- 102400000739 Corticotropin Human genes 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 description 1
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 1
- 241000224432 Entamoeba histolytica Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 102400000525 Fibrinopeptide A Human genes 0.000 description 1
- 101800000974 Fibrinopeptide A Proteins 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 102400000988 Met-enkephalin Human genes 0.000 description 1
- 108010042237 Methionine Enkephalin Proteins 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 208000032976 Neuroendocrine carcinoma of pancreas Diseases 0.000 description 1
- 108010061952 Orosomucoid Proteins 0.000 description 1
- 102000012404 Orosomucoid Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 108010003044 Placental Lactogen Proteins 0.000 description 1
- 239000000381 Placental Lactogen Substances 0.000 description 1
- 229940122791 Plasmin inhibitor Drugs 0.000 description 1
- 102000007584 Prealbumin Human genes 0.000 description 1
- 108010071690 Prealbumin Proteins 0.000 description 1
- 101710185022 Proteasome-activating nucleotidase 2 Proteins 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- URWAJWIAIPFPJE-UHFFFAOYSA-N Rickamicin Natural products O1CC(O)(C)C(NC)C(O)C1OC1C(O)C(OC2C(CC=C(CN)O2)N)C(N)CC1N URWAJWIAIPFPJE-UHFFFAOYSA-N 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 229930192786 Sisomicin Natural products 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 102000009488 Thyroxine-Binding Proteins Human genes 0.000 description 1
- 108010048889 Thyroxine-Binding Proteins Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 102000011409 Transcobalamins Human genes 0.000 description 1
- 108010023603 Transcobalamins Proteins 0.000 description 1
- 102000050760 Vitamin D-binding protein Human genes 0.000 description 1
- 101710179590 Vitamin D-binding protein Proteins 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- WOPZMFQRCBYPJU-NTXHZHDSSA-N beta-endorphin Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CC=CC=C1 WOPZMFQRCBYPJU-NTXHZHDSSA-N 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 235000020964 calcitriol Nutrition 0.000 description 1
- 239000011612 calcitriol Substances 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229910000071 diazene Inorganic materials 0.000 description 1
- 229960000648 digitoxin Drugs 0.000 description 1
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940007078 entamoeba histolytica Drugs 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- 229960001348 estriol Drugs 0.000 description 1
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 1
- 229960002767 ethosuximide Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 239000002350 fibrinopeptide Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- JKKCSFJSULZNDN-UHFFFAOYSA-N gonyautoxin v Chemical compound N=C1NC(COC(=O)NS(O)(=O)=O)C2NC(=N)NC22C(O)(O)CCN21 JKKCSFJSULZNDN-UHFFFAOYSA-N 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 229960000808 netilmicin Drugs 0.000 description 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 201000002530 pancreatic endocrine carcinoma Diseases 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000002806 plasmin inhibitor Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 102000029752 retinol binding Human genes 0.000 description 1
- 108091000053 retinol binding Proteins 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 229960005456 sisomicin Drugs 0.000 description 1
- URWAJWIAIPFPJE-YFMIWBNJSA-N sisomycin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CN)O2)N)[C@@H](N)C[C@H]1N URWAJWIAIPFPJE-YFMIWBNJSA-N 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 229940035722 triiodothyronine Drugs 0.000 description 1
- 239000000015 trinitrotoluene Substances 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Abstract
Description
【発明の詳細な説明】
［産業上の利用分野］
この発明は、抗原抗体反応を利用したタンパク質、ペプ
チド、ハプテンの検査方法及びそれに用いられる検査試
薬に関する。DETAILED DESCRIPTION OF THE INVENTION [Industrial Application Field] The present invention relates to a method for testing proteins, peptides, and haptens using antigen-antibody reactions, and a test reagent used therefor.
［従来の技術］
従来より抗原抗体反応を利用したタンパク質、ハプテン
（不完全抗原）の検出方法として、蛍光イムノアッセイ
、発光イムノアッセイ、ラジオイムノアッセイ等が知ら
れている。例えば蛍光イムノアッセイは図に示すように
予め抗体分子１のＦＣ部（抗原と結合しない部分）にフ
ルオレッセイン、イソチオシアネートなどの蛍光色素２
を結合させておく。この抗体と所定のタンパク質あるい
はハプテンを反応させた後、抗体と結合した抗原３を必
要に応じＢ／Ｆ分離（結合分子と遊離分子の分離）を行
い、結合分子あるいは遊離分子の蛍光測定を行うもので
ある。[Prior Art] Fluorescence immunoassays, luminescence immunoassays, radioimmunoassays, and the like have been known as methods for detecting proteins and haptens (incomplete antigens) using antigen-antibody reactions. For example, in a fluorescent immunoassay, as shown in the figure, a fluorescent dye 2 such as fluorescein or isothiocyanate is added to the FC region (the part that does not bind to the antigen) of an antibody molecule 1 in advance.
Let's combine them. After reacting this antibody with a predetermined protein or hapten, the antigen 3 bound to the antibody is subjected to B/F separation (separation of bound molecules and free molecules) as necessary, and the fluorescence of the bound molecules or free molecules is measured. It is something.
一方、ラジオイムノアッセイは１２５■、８２Ｐ１８Ｈ
等の放射性同位体でラベルした抗原あるいは抗体を用い
て抗体あるいは抗原の量を測定するもので、血中ホルモ
ン量の定量など極めて微量の物質の定量に用いられる。On the other hand, radioimmunoassay is 125■, 82P18H
This method measures the amount of antibodies or antigens using antigens or antibodies labeled with radioactive isotopes such as, etc., and is used to quantify extremely small amounts of substances such as the amount of hormones in the blood.
［発明が解決しようとする課題］
ところで、このような従来のタンパク質等の検出方法に
おいては、特定の被検物質に対してこれと特異的に反応
する特定の抗体のみを含む試薬が用いられていた。従っ
て多種類のタンパク質、ペプチドあるいはハプテンを含
有する検体中の各被検物質を検出する場合、検査項目数
に対応する数のサンプルを用意する必要があり、サンプ
ルあるいは抗原量が極めて少ない場合には検査が困難で
あった。又、検出操作も各検査項目毎に行なわなければ
ならず、非常に手間がかかった。[Problems to be Solved by the Invention] Incidentally, in such conventional methods for detecting proteins, etc., a reagent containing only a specific antibody that specifically reacts with a specific test substance is used. Ta. Therefore, when detecting each test substance in a specimen containing many types of proteins, peptides, or haptens, it is necessary to prepare a number of samples corresponding to the number of test items. Inspection was difficult. Furthermore, the detection operation had to be performed for each inspection item, which was very time-consuming.
この発明は上記従来の検出方法の欠点を解消し、−回の
操作で多種類のタンパク質、ペプチドあるいはハプテン
等の被検物質を検出することが可能な検査方法および検
査試薬を提供せんとするものである。The present invention aims to solve the drawbacks of the conventional detection methods described above, and to provide a test method and test reagent that can detect a wide variety of test substances such as proteins, peptides, or haptens in just one operation. It is.
［課題を解決するための手段］
このような目的を達成する本発明の検査方法は、特定の
抗原、ハプテン等の被検物質にそれぞれ特異的に反応す
る２種以上の抗体であって、各々識別可能な標識でラベ
ルされているものを、検体と接触させて検体中に含まれ
る特定の被検物質と結合させて、抗体と結合した特定の
被検物質の各々を標識で識別するものであり、特に標識
は、放射線種の異なる２種以上の放射性同位元素、極大
吸収波長の異なる色素、蛍光極大波長の異なる蛍光色素
、極大発光波長の異なる物質又はこれらの組合せである
。[Means for Solving the Problems] The testing method of the present invention that achieves the above object uses two or more types of antibodies, each of which specifically reacts with a test substance such as a specific antigen or hapten. An antibody labeled with an identifiable label is brought into contact with a sample and binds to a specific test substance contained in the sample, and each specific test substance bound to an antibody is identified by the label. In particular, the label is two or more radioisotopes with different radiation species, dyes with different maximum absorption wavelengths, fluorescent dyes with different maximum fluorescence wavelengths, substances with different maximum emission wavelengths, or a combination thereof.
ここで、本発明の検査方法の被検物質としては、ホルモ
ン類、酵素類、腫瘍マーカー類、ウィルス類、血漿タン
パク類、薬剤、その他生理活性物質を挙げることかでき
る。Here, examples of test substances for the testing method of the present invention include hormones, enzymes, tumor markers, viruses, plasma proteins, drugs, and other physiologically active substances.
ホルモン類としては、例えば甲状腺刺激ホルモン、卵胞
刺激ホルモン、黄体形成ホルモン、副腎皮質刺激ホルモ
ン、成長ホルモン、乳腺刺激ホルモン、サイロキシン、
トリヨードサイロニン、カルシトニン、コルチゾール、
コルチコステロン、エストラジオール、エストリオール
、プロジェステロン、テストステロン、胎盤性ゴナドト
ロピン、胎盤性ラクトゲン、インスリン、グルカゴン、
セクレチン、ガストリンなとがある。酵素では例えばプ
ロテアーゼ、システインプロテアーゼ力テブンンＢ、Ｈ
，Ｌ、乳酸脱水素酵素などかある。腫瘍マーカーでは、
ＣＥＡ、ＡＦＰＳＰＯＡ （ｐａｎ−ｃｒｅａｔｉｃ
ｏｎｃｏｆｅｔａｌ ａｎｔｉｇｅｎ） 、Ｂ Ｆ Ｐ
（ｂａｓｉｃｆｅｔｏ ｐｒｏｔｅｉｎ） 、Ｐ Ａ
（ｐｒｏｓｔａｔｅ ａｎｔｉｇｅｎ） 、ＣＡ１９
−９、ＣＡ１２５、ＣＡ１５−３、ＣＡ３０、ＤｔＪ−
ＰＡＮ−２などがある。ウィルスなどは例えばＢ型肝炎
ウィルス、ロタウィルス、アデノウィルス、サイトメガ
ロウィルス、ヘルペスウィルス、インフルエンザウィル
ス、エンテロウィルス、シンシアルウィルス、ナイセリ
ア、パピローマ、エイズ、マイコプラズマ、トキソプラ
ズマ、クラミジア、大腸菌、赤痢アメーバ、麻疹、おた
ふくかぜ、結核菌などがある。血漿タンパクでは、プレ
アルブミン、アルブミン、α１−フェトプロティン、α
１−ミクログロブリン、α１−酸グリコプロテイン、α
ＩＴ−グリコプロティン、α１アンチトリプシン、α２
Ｂ−グリコプロティン、ビタミンＤ−結合タンパク、α
１−リポプロティン、サイロキシン−結合タンパク、Ｚ
ｎ−α２グリコプロテイン、セルロプラスミン、レチノ
ール−結合タンパク、α２Ｈ３−グリコプロティン、α
２−グリコプロティン、ハプトグロブリン、フレーβリ
ポプロティン、トランスコバラミン、ヘモベキシン、ス
テロイド−結合−βグロブリン、β２−ミクログロブリ
ン、β２−グリコプロティン、β−リポプロティン、免
疫グロブリン、免疫グロブリンＡ２免疫グロブリンＭ１
免疫グロブリンＤ１免疫グロブリンＥ１免疫グロブリン
Ｇなどがある。血液凝固系および線溶系ではプロトロン
ビン、プラスミノダン、フィブリノゲン、第Ｖ因子、第
■因子、第■因子、第■因子、第Ｘ因子、第Ｘ因子、第
Ｘ１因子、第Ｘ■因子、第Ｘ■因子、アンチスロンビン
■、Ｃ２−プラスミン阻害因子、フィブリノペプチドＡ
１フィブリノペプチドＢβ、ティシュプラスミノーゲン
活性化因子などがある。Hormones include, for example, thyroid stimulating hormone, follicle stimulating hormone, luteinizing hormone, adrenocorticotropic hormone, growth hormone, mammary gland stimulating hormone, thyroxine,
triiodothyronine, calcitonin, cortisol,
Corticosterone, estradiol, estriol, progesterone, testosterone, placental gonadotropin, placental lactogen, insulin, glucagon,
These include secretin and gastrin. For enzymes, for example, protease, cysteine protease, B, H
, L, lactate dehydrogenase, etc. For tumor markers,
CEA, AFPSPOA (pan-creatic
oncofetal antigen), BFP
(basicfeto protein), P A
(prostate antigen), CA19
-9, CA125, CA15-3, CA30, DtJ-
Examples include PAN-2. Examples of viruses include hepatitis B virus, rotavirus, adenovirus, cytomegalovirus, herpes virus, influenza virus, enterovirus, synthial virus, Neisseria, papilloma, AIDS, mycoplasma, toxoplasma, chlamydia, Escherichia coli, Entamoeba histolytica, measles, These include mumps and tuberculosis bacteria. Plasma proteins include prealbumin, albumin, α1-fetoprotein, α
1-microglobulin, α1-acid glycoprotein, α
IT-glycoprotein, α1 antitrypsin, α2
B-glycoprotein, vitamin D-binding protein, α
1-lipoprotein, thyroxine-binding protein, Z
n-α2 glycoprotein, ceruloplasmin, retinol-binding protein, α2H3-glycoprotein, α
2-glycoprotein, haptoglobulin, Frey β-lipoprotein, transcobalamin, hemovexin, steroid-bound β-globulin, β2-microglobulin, β2-glycoprotein, β-lipoprotein, immunoglobulin, immunoglobulin A2 immunoglobulin M1
These include immunoglobulin D, immunoglobulin E, and immunoglobulin G. In the blood coagulation system and fibrinolytic system, prothrombin, plasminodan, fibrinogen, factor V, factor ■, factor ■, factor ■, factor X, factor X, factor X1, factor X■, factor X■ , antithrombin ■, C2-plasmin inhibitor, fibrinopeptide A
1 fibrinopeptide Bβ, tissue plasminogen activator, etc.
プロテアーゼ・インヒビターではＣ２−マクログロブリ
ン、バプトグロビン、セルロブラスミンなどがある。補
体ではＣ１ｑ因子、Ｃ１ｒ因子、Ｃ１ｓ因子、Ｃ４因子
、Ｃ５因子、Ｃ６因子、Ｃ７因子、Ｃ８因子、Ｃ９因子
などがある。薬剤では抗てんかん剤例えばエトスクシミ
ド、カルバマゼミン、パルプロ酸、フェニトイン、フエ
ノバルビタール、ブリミドンなどがあり、アミノ酸配糖
体系抗生物質ではアミカシン、カナマイシン、ゲンタマ
イシン、シソマイシン、トラブトマイシン、ネチルマイ
シンなどがあり、循環器側薬ではキニジン、ジギトキシ
ン、ジゴキシン、ジンブラミド、テオフィリン、ブロカ
インアミト、Ｎ−アセチルブロカインアミド、リドカイ
ンなどがあり、抗悪性腫瘍薬ではメトトレキサートなど
があり、生理活性物質ではボツリヌス毒素Ａ１ボツリヌ
ス毒素Ｂ１ボツリヌス毒素Ｆ１コレラ毒素、インターフ
ェロン、サイモボエチン、ブラジキニン、β−エンドル
フィン、Ｍｅｔ−エンケファリン、サブスタンスＰ、２
’、５’−オリゴアデニル酸、ｅ−ＡＭＰ、ピリドキサ
ミン、１α、２５−ジヒドロキシビタミンＤ３、ジゴキ
シン、ジニトロフェノール−ロイシン、トリニトロトル
エン、プロスタグランジン、プロスタサイクリン、トロ
ンボキサン、ロイコトリエンなどがある。Protease inhibitors include C2-macroglobulin, baptoglobin, and celluloblasmin. Complement includes C1q factor, C1r factor, C1s factor, C4 factor, C5 factor, C6 factor, C7 factor, C8 factor, and C9 factor. Antiepileptic drugs include ethosuximide, carbamazemine, palproic acid, phenytoin, phenobarbital, and brimidone, and amino acid glycoside antibiotics include amikacin, kanamycin, gentamicin, sisomicin, trabutomycin, and netilmicin. Side drugs include quinidine, digitoxin, digoxin, ginbramide, theophylline, brocainamide, N-acetylbrocainamide, and lidocaine, anti-cancer drugs include methotrexate, and physiologically active substances include botulinum toxin A1, botulinum toxin B1, and botulinum toxin F1. Cholera toxin, interferon, thymoboetin, bradykinin, β-endorphin, Met-enkephalin, substance P, 2
',5'-oligoadenylic acid, e-AMP, pyridoxamine, 1α,25-dihydroxyvitamin D3, digoxin, dinitrophenol-leucine, trinitrotoluene, prostaglandin, prostacyclin, thromboxane, leukotriene, and the like.
そしてこれら複数種の抗体は各々識別可能な標識でラベ
ルされている。標識としては放射性同位元素、蛍光色素
、発光色素等の色素が用いられる。Each of these multiple types of antibodies is labeled with an identifiable label. As the label, dyes such as radioactive isotopes, fluorescent dyes, and luminescent dyes are used.
例えば放射性同位元素であればＩ２５１ 、Ｂ２ｐ、８
Ｈなどエネルギービークの異なるものが用いられる。For example, if it is a radioactive isotope, I251, B2p, 8
Types with different energy peaks such as H are used.
また放射線以外の標識として用いられる色素は以下に挙
げる比色法、蛍光法、発光法等の検知方法で検知される
ものが用いられる。比色法では、基質に１．２−フユニ
レンジアミン或いは３，３゜５．５゛−テトラメチルベ
ンチジンを用いるペルオキシダーゼ法、基質に２−ニト
ロフェニル・β−Ｄガラクトシドを用いるβ−Ｄガラク
トシダーゼ法、基質に４−ニトロフェニル・フォスフェ
ートを用いるアルカリフォスファターゼ法などの方法、
蛍光法では蛍光色素としてアリルナフタレンスルホン酸
類（ＡＮＳ）、フルオレセインインチオシアネ−１−（
ＦＩＴＣ）、テトラメチルローダミンイソチオシアネー
ト（ＴＬＩ）、３−カルボエトキシ−７−ヒドロキシク
マリン（ＣＥＨ）、ダンシルクロリド（ＤＮＳ−Ｃ！Ｑ
）などを用いる方法や、基質に４−ヒドロキシフェニル
酢酸あるいは３−（４−ヒドロキシフェニル）プロピオ
ン酸を用いるペルオキシダーゼ法、基質に４−メチルウ
ムベリフェリル・β−Ｄガラクトシドを用いるβ−Ｄガ
ラクトシダーゼ法、基質に４−メチルウムベリフェリル
・フォスフェートを用いるアルカリフォスファターゼ法
などの方法、生物発光法では、基質にグルコース−６−
リン酸脱水素酵素を用いる脱水素酵素法、基質に２−二
トロフェニル・βＤガラクトシドを用いるβ−Ｄガラク
トシダーゼ法などの方法、化学発光法では、ルミノール
Ｈ２０，系によるペルオキシダーゼ法などの公知の方法
を用いることができる。これらは吸収波長、蛍光波長、
発光波長のそれぞれ異なるものを組合せて用いる。例え
ばＦＩＴＣ，ＴＩ＝１及びＣＥＨのＩｇＧ結合物の蛍光
波長は、それぞれ４９５ ｎｍ、。In addition, dyes used as labels other than radiation include those that can be detected by the following detection methods such as colorimetry, fluorescence, and luminescence. In the colorimetric method, the peroxidase method uses 1,2-fuynylenediamine or 3,3゜5.5゛-tetramethylbenzidine as a substrate, and the β-D method uses 2-nitrophenyl β-D galactoside as a substrate. Methods such as galactosidase method, alkaline phosphatase method using 4-nitrophenyl phosphate as a substrate,
In the fluorescence method, allylnaphthalene sulfonic acids (ANS) and fluorescein inthiocyanate-1-(
FITC), tetramethylrhodamine isothiocyanate (TLI), 3-carboethoxy-7-hydroxycoumarin (CEH), dansyl chloride (DNS-C!Q)
), peroxidase method using 4-hydroxyphenylacetic acid or 3-(4-hydroxyphenyl)propionic acid as a substrate, and β-D galactosidase method using 4-methylumbelliferyl β-D galactoside as a substrate. , methods such as the alkaline phosphatase method that uses 4-methylumbelliferyl phosphate as a substrate, and bioluminescence methods that use glucose-6-
Methods such as dehydrogenase method using phosphate dehydrogenase, β-D galactosidase method using 2-nitrophenyl βD galactoside as a substrate, and known methods such as peroxidase method using Luminol H20 system for chemiluminescence method. can be used. These are absorption wavelength, fluorescence wavelength,
A combination of different emission wavelengths is used. For example, the fluorescence wavelength of IgG conjugates of FITC, TI=1, and CEH is 495 nm, respectively.
５５２ｒ＋ｍ、 ４００ｎｍてあり、これらを組合せて
複数（３種類）の抗体にラベルする。552r+m and 400 nm, and these are combined to label multiple (3 types) antibodies.
これらの標識化法にはグルタルアルデヒド法、過よう素
酸法、マレイミド法（ヒンジ法）、ピリジル・ジスルフ
ィド法、酸無水物法、カーポジイミド法、ジイミドエス
テル法、過よう素酸酸化法、ミクサシネート法、ジアル
デヒドへの酸化法、オキシム化法などの公知の方法を用
いることができる。These labeling methods include glutaraldehyde method, periodic acid method, maleimide method (hinge method), pyridyl disulfide method, acid anhydride method, carposiimide method, diimide ester method, periodic acid oxidation method, and mixacinate method. Known methods such as oxidation method, oxidation method to dialdehyde, and oxime method can be used.
本発明の検査試薬は、特定の抗原、ハプテンにそれぞれ
特異的に反応する２種以−にの抗体であって、このよう
に識別可能な標識でラベルされた抗体を含有するもので
あり、これら抗体を混合して検査試薬として用いる。通
常、水、水−アルコール等の適当な溶媒の溶液として用
いる。The test reagent of the present invention contains two or more antibodies that react specifically with specific antigens and haptens, and which are labeled with such distinguishable labels. Antibodies are mixed together and used as a test reagent. It is usually used as a solution in a suitable solvent such as water or water-alcohol.
本発明の検査方法及び検査試薬は、沈澱法、不溶化固相
法等に適用できる。例えば沈澱法の場合、本発明の検査
試薬を被検液と混合した後、硫酸ナトリウムや硫酸アン
モニウムにより沈澱を生じさせＢ／Ｆ分離を行ない、生
成した沈澱物の放射線測定、吸光分光測定、蛍光分光測
定の測定を行なう。そして、用いられた標識に対応する
波長における放射線の量、あるいは蛍光量を計測し被検
物質を定量する。又、不溶化抗体固相法であれば、標識
でラベルされた複数種の抗体をアガロースゲル、プロテ
ィンＡ−セファロース等の不溶化担体により固相して、
被検液と接触させた後、洗浄によりＢ／Ｆ分離を行ない
、結合型（Ｂ）の放射線スペクトル、蛍光スペクトルを
測定する。以下、沈澱法と同様にして被検物質を定量す
る。The testing method and testing reagent of the present invention can be applied to precipitation methods, insolubilization solid phase methods, and the like. For example, in the case of the precipitation method, the test reagent of the present invention is mixed with a test solution, then precipitated with sodium sulfate or ammonium sulfate, B/F separation is performed, and the resulting precipitate is subjected to radiation measurement, absorption spectrometry, and fluorescence spectroscopy. Perform measurements. Then, the amount of radiation or fluorescence at the wavelength corresponding to the label used is measured to quantify the amount of the test substance. In addition, in the case of the insolubilized antibody solid-phase method, multiple types of antibodies labeled with a label are solid-phased with an insolubilized carrier such as agarose gel or protein A-Sepharose.
After contacting with the test liquid, B/F separation is performed by washing, and the radiation spectrum and fluorescence spectrum of the bound type (B) are measured. Thereafter, the test substance is quantified in the same manner as the precipitation method.
［作用コ
各々識別可能な標識でラベルされている２種以上の抗体
と被検液とを接触させると、これら２種以上の抗体は各
々被検液中の特定の被検物質と特異的に抗原抗体反応を
生じ結合する。この混合物を公知の方法でＢ／Ｆ分離し
た後、抗体と結合している被検物質の混合物を当該標識
を検出する所定の方法、例えば放射線測定、吸光分光測
定、蛍光分光測定等の方法で測定する。各抗体に予め結
合した標識はそれぞれ、放射線種、最大吸収波長あるい
は蛍光極大波長を異にし識別可能であるので一回の測定
でそれぞれの抗原を測定することができる。[Action] When two or more antibodies, each labeled with a distinguishable label, are brought into contact with a test solution, each of these two or more antibodies will react specifically with a specific test substance in the test solution. Antigen-antibody reaction occurs and binds. After this mixture is subjected to B/F separation using a known method, the mixture of the test substance bound to the antibody is subjected to a predetermined method for detecting the label, such as radiation measurement, absorption spectrometry, fluorescence spectrometry, etc. Measure. Since the labels pre-bound to each antibody can be identified by having different radiation species, maximum absorption wavelengths, or maximum fluorescence wavelengths, each antigen can be measured in a single measurement.
［発明の効果］
以上の説明からも明らかなように、本発明の検査方法及
び検査試薬によれば、それぞれ異なる標識物質を用いた
複数種の抗体を一つの被検体と反応させればよいので、
−度の操作で複数の検査項目を検査することができる。[Effects of the Invention] As is clear from the above explanation, according to the test method and test reagent of the present invention, it is only necessary to react multiple types of antibodies using different labeling substances with one analyte. ,
- Multiple inspection items can be inspected with one-time operation.
従って、極めて微量の被検物質であっても効率よく検査
することができる。Therefore, even an extremely small amount of a test substance can be efficiently tested.
図は抗原抗体反応を利用した検査方法の一例を示す図で
ある。
１・・・・・・抗体
２・・・・・・標識
３・・・・・・抗原The figure shows an example of a testing method using an antigen-antibody reaction. 1... Antibody 2... Label 3... Antigen
Claims (1)
的に反応する２種以上の抗体であって、各々識別可能な
標識でラベルされているものを、検体と接触させて前記
検体中に含まれる特定の被検物質と結合させて、前記抗
体と結合した前記特定の被検物質の各々を前記標識で識
別することを特徴とする検査方法。 ２、前記標識が放射線の異なる２種以上の放射性同位元
素であることを特徴とする請求項１記載の検査方法。 ３、前記標識が極大吸収波長の異なる物質、極大蛍光波
長の異なる物質、極大発光波長の異なる物質又はその組
合せであることを特徴とする請求項１記載の検査方法。 ４、前記標識が極大吸収波長の異なる物質、極大蛍光波
長の異なる物質、極大発光波長の異なる物質又はその組
合せと放射性同位元素との組合せであることを特徴とす
る請求項１記載の検査方法。 ５、特定の抗原、ハプテンにそれぞれ特異的に反応する
２種以上の抗体であって、各々識別可能な標識でラベル
されているものを含有し、前記抗体と結合した特定の被
検物質の各々を前記標識で識別可能とすることを特徴と
する検査試薬。[Claims] 1. Two or more antibodies that react specifically with a test substance such as a specific antigen or hapten, each labeled with a distinguishable label, are brought into contact with a specimen. A testing method characterized in that each of the specific test substances bound to the antibody is identified by the label by allowing the antibody to bind to a specific test substance contained in the specimen. 2. The inspection method according to claim 1, wherein the label is two or more types of radioisotopes with different radiations. 3. The inspection method according to claim 1, wherein the label is a substance having a different maximum absorption wavelength, a substance having a different maximum fluorescence wavelength, a substance having a different maximum emission wavelength, or a combination thereof. 4. The testing method according to claim 1, wherein the label is a substance having a different maximum absorption wavelength, a substance having a different maximum fluorescence wavelength, a substance having a different maximum emission wavelength, or a combination thereof and a radioactive isotope. 5. Contains two or more antibodies that specifically react with specific antigens and haptens, each labeled with a distinguishable label, and each specific test substance bound to the antibody. A test reagent characterized in that it can be identified by the label.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8195190A JPH03279860A (en) | 1990-03-29 | 1990-03-29 | Inspecting method and inspecting reagent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8195190A JPH03279860A (en) | 1990-03-29 | 1990-03-29 | Inspecting method and inspecting reagent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH03279860A true JPH03279860A (en) | 1991-12-11 |
Family
ID=13760808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP8195190A Pending JPH03279860A (en) | 1990-03-29 | 1990-03-29 | Inspecting method and inspecting reagent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH03279860A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002544488A (en) * | 1999-05-07 | 2002-12-24 | クアンタム ドット コーポレイション | Methods for detecting analytes using semiconductor nanocrystals |
| JP2003531734A (en) * | 2000-04-06 | 2003-10-28 | クアンタム・ドット・コーポレーション | Discriminable spectral barcode method and system |
| JP2003532119A (en) * | 2000-05-04 | 2003-10-28 | デイド・ベーリング・マルブルク・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング | Compositions for use in detecting multiple analytes |
-
1990
- 1990-03-29 JP JP8195190A patent/JPH03279860A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002544488A (en) * | 1999-05-07 | 2002-12-24 | クアンタム ドット コーポレイション | Methods for detecting analytes using semiconductor nanocrystals |
| JP2003531734A (en) * | 2000-04-06 | 2003-10-28 | クアンタム・ドット・コーポレーション | Discriminable spectral barcode method and system |
| JP2003532119A (en) * | 2000-05-04 | 2003-10-28 | デイド・ベーリング・マルブルク・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング | Compositions for use in detecting multiple analytes |
| JP4796259B2 (en) * | 2000-05-04 | 2011-10-19 | シーメンス・ヘルスケア・ダイアグノスティックス・プロダクツ・ゲーエムベーハー | Composition for use in the detection of multiple analytes |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0398913B1 (en) | Test method and reagent kit therefor | |
| Zhao et al. | Chemiluminescence immunoassay | |
| Locascio-Brown et al. | Liposome flow injection immunoassay: implications for sensitivity, dynamic range, and antibody regeneration | |
| US4080264A (en) | Immunoassay by light scattering spectroscopy | |
| US4222744A (en) | Assay for ligands | |
| Hempen et al. | Labeling strategies for bioassays | |
| AU2009333937B2 (en) | Quantitative analyte assay device and method | |
| EP0191575A1 (en) | Homogeneous fluorescence immunoassay using a light absorbing material | |
| JPS61277059A (en) | Analysis of plural items | |
| WO2007111847A2 (en) | Use of additives for the reduction of non-specific binding in assays | |
| US5389523A (en) | Liposome immunoanalysis by flow injection assay | |
| US4436826A (en) | Tagged immunoassay | |
| JP4033853B2 (en) | Solid phase assay for detection of ligands | |
| Liu et al. | Flow injection solid-phase chemiluminescent immunoassay using a membrane-based reactor | |
| JP5270672B2 (en) | Analyte detection method | |
| US8043866B2 (en) | Immunochromatography method | |
| JPS63127160A (en) | Detection of specific protein | |
| JPH03279860A (en) | Inspecting method and inspecting reagent | |
| JP2893772B2 (en) | Immunoassay | |
| US4433060A (en) | Chemiluminescent immunoassays with triphenylmethane dyes activated by H.sub. O2 and a chloramine | |
| GB2223096A (en) | Detecting a selected species | |
| JPS635265A (en) | Method for immunoassay | |
| JPH0192661A (en) | Immunoassay method | |
| JPH04106470A (en) | Particulate immune measurement method and apparatus | |
| JPS61110059A (en) | Immunological analysis |